FDA Clearance Tracker · P970012
MEDTRONIC.KAPPA 400 SERIES PACEMAKERS
Last checked: Nov 20, 2026Latest source record: Jan 30, 1998 (this decision)Source: openFDAMethods & limitations
Decided
Jan 30, 1998
Approved
Time to decision
357 days
Received Feb 7, 1997. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P970012
- Device name
- MEDTRONIC.KAPPA 400 SERIES PACEMAKERS
- Applicant
- Medtronic, Inc.
- Applicant location
- Mounds View, MN
- Received
- Feb 7, 1997
- Decided
- Jan 30, 1998
- Decision
- Approved
- Supplements
- 96 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the Medtronic.Kappa 400 Series Pacemakers, which includes; Medtronic.Kappa KDR 401/403 & KSR 401/403 Implantable Pulse Generators w/Medtronic.Vision (Model 9952E) Software, & Medtronic Model 9462 Remote Assistant. These devices are indicated for the following: 1)Rate adaptive pacing in patients who may benefit from increased pacing rates concurrent w/increases in activity and/or minute ventilation; 2)Accepted patient conditions warranting chronic cardiac pacing which include: a)symptomatic parosysmal or permanent 2nd or 3rd degree AV block; b) symptomatic bilateral bundle branch block; c) symptomatic parosysmal or transient sinus node dysfunctions w/ or without associated AV conduction disorders; d) bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias; and e) vasovagal syndromes or hypersensitive carotid sinus syndromes. 3) Medtronic.Kappa 400 Series Pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifcally indicated for treatment of conduction disorders that require restoration of both rate & AV synchrony, which include: a) various degress of AV block to maintain the atrial contribution to cardiac output; and b) VVI intolerance (e.g., pacemaker syndrome) in the presence of persistent sinus rhythm.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NVZ. The earliest in FDA's data is P890003, decided Aug 24, 1989.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.